[go: up one dir, main page]

DK0739355T3 - Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf - Google Patents

Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf

Info

Publication number
DK0739355T3
DK0739355T3 DK95909223T DK95909223T DK0739355T3 DK 0739355 T3 DK0739355 T3 DK 0739355T3 DK 95909223 T DK95909223 T DK 95909223T DK 95909223 T DK95909223 T DK 95909223T DK 0739355 T3 DK0739355 T3 DK 0739355T3
Authority
DK
Denmark
Prior art keywords
proteins
kallikrein
analogs
inhibiting
disclosed
Prior art date
Application number
DK95909223T
Other languages
English (en)
Inventor
Robert Charles Ladner
William Markland
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/208,264 external-priority patent/US6057287A/en
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK0739355T3 publication Critical patent/DK0739355T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK95909223T 1994-01-11 1995-01-11 Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf DK0739355T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17996494A 1994-01-11 1994-01-11
US08/208,264 US6057287A (en) 1994-01-11 1994-03-10 Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PCT/US1995/000299 WO1995021601A2 (en) 1994-01-11 1995-01-11 Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof

Publications (1)

Publication Number Publication Date
DK0739355T3 true DK0739355T3 (da) 2005-01-24

Family

ID=26875859

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909223T DK0739355T3 (da) 1994-01-11 1995-01-11 Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf

Country Status (10)

Country Link
US (3) US5795865A (da)
EP (1) EP0739355B1 (da)
JP (1) JP3805785B2 (da)
AT (1) ATE275583T1 (da)
CA (1) CA2180950C (da)
DE (1) DE69533472T2 (da)
DK (1) DK0739355T3 (da)
ES (1) ES2227545T3 (da)
PT (1) PT739355E (da)
WO (1) WO1995021601A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) * 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
CA2180950C (en) * 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
PT737207E (pt) * 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100356956B1 (ko) * 1996-03-11 2003-03-15 베이어 코오포레이숀 사람비쿠닌
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CA2289117A1 (en) * 1997-05-12 1998-11-19 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
WO1999061615A1 (en) * 1998-05-28 1999-12-02 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6087473A (en) 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6380354B1 (en) * 1998-09-03 2002-04-30 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
ATE254473T1 (de) * 1998-12-22 2003-12-15 Bayer Ag Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
WO2001046230A2 (en) * 1999-12-22 2001-06-28 Zymogenetics, Inc. Kunitz domain polypeptide zkun11
WO2001047958A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Kunitz domain polypeptide zkun10
US20020004224A1 (en) * 2000-02-29 2002-01-10 Sheppard Paul O. Kunitz domain polypeptide zkun8
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
NZ534310A (en) 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) * 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
ES2395014T3 (es) * 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
CA2512590A1 (en) * 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
BRPI0409557B8 (pt) 2003-04-04 2021-05-25 Univ Lausanne proteína recombinante inibidora de calicreína, sequência de dna, vetor de expressão, composição farmacêutica, uso da composição farmacêutica, método de produção da proteína recombinanete e kits de diagnóstico
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
US7432238B2 (en) * 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
AU2011218732B2 (en) * 2004-09-27 2013-07-04 Takeda Pharmaceutical Company Limited Kallikrein Inhibitors and Uses Thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008520729A (ja) * 2004-11-22 2008-06-19 ダイアックス コーポレーション プラスミン阻害療法
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
AR054165A1 (es) * 2005-07-13 2007-06-06 Avidia Inc Proteinas de union a il-6
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
DK1981519T3 (da) 2005-12-29 2018-02-19 Dyax Corp Proteaseinhibering
US8993719B2 (en) * 2005-12-29 2015-03-31 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain I of TFPI-2
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
EP2374472B9 (en) * 2006-03-16 2019-06-12 Dyax Corp. Compositions and methods for treating ophthalmic disorders
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008288772A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
SMT201800563T1 (it) 2013-01-20 2018-11-09 Dyax Corp Valutazione e trattamento di disturbi mediati da bradichinina
HUE044285T2 (hu) 2013-01-20 2019-10-28 Dyax Corp PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
PT3096798T (pt) 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
HK1250995A1 (zh) 2015-03-30 2019-01-18 Takeda Pharmaceutical Company Limited 血浆激肽释放酶抑制剂及预防遗传性血管神经性水肿发作的用途
MX2018001786A (es) 2015-08-13 2018-06-06 Dyax Corp Tubos de extraccion de sangre segregada que contienen inhibidores de proteasa para la evaluacion de activacion del sistema de contacto.
DK3365685T3 (da) 2015-10-19 2021-03-01 Dyax Corp Immunoassay til påvisning af spaltet højmolekylært kininogen
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CN117169508A (zh) 2016-09-16 2023-12-05 武田药品工业株式会社 用于与接触活化系统相关的疾病的代谢产物生物标记
CN109716138B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记
WO2018053260A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Rna biomarkers for hereditary angioedema
HUP1700012A2 (en) 2017-01-06 2018-07-30 Evolveritas Kft Novel proteins and use thereof
WO2020047352A1 (en) 2018-08-30 2020-03-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US20200317815A1 (en) 2019-03-14 2020-10-08 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2021146160A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
JP2023521667A (ja) 2020-04-04 2023-05-25 武田薬品工業株式会社 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
JP2025522757A (ja) 2022-06-30 2025-07-17 武田薬品工業株式会社 ラナデルマブ治療のためのタンパク質バイオマーカー
JP2025534392A (ja) 2022-09-29 2025-10-15 エヴォルヴェルタシュ バイオテクノロギアイ コルラートルト フェレレーシュシェーギュー タールシャシャーグ 足場タンパク質及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
EP0285123A3 (en) * 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
CA2180950C (en) * 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof

Also Published As

Publication number Publication date
ES2227545T3 (es) 2005-04-01
US5795865A (en) 1998-08-18
ATE275583T1 (de) 2004-09-15
WO1995021601A3 (en) 1995-09-21
JP3805785B2 (ja) 2006-08-09
PT739355E (pt) 2005-01-31
DE69533472D1 (de) 2004-10-14
EP0739355B1 (en) 2004-09-08
US5994125A (en) 1999-11-30
JPH09511131A (ja) 1997-11-11
US6333402B1 (en) 2001-12-25
WO1995021601A2 (en) 1995-08-17
EP0739355A1 (en) 1996-10-30
DE69533472T2 (de) 2006-01-12
CA2180950C (en) 2005-03-29
CA2180950A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
DK0739355T3 (da) Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf
CA2180954A1 (en) Inhibitors of human plasmin derived from the kunitz domains
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
FI880464A0 (fi) Bekaempningsmedel mot tandplaque och -karies.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
NO965098L (no) Perfluoralkylketoninhibitorer av elastase og fremgangsmåter for fremstilling av disse
IL81964A (en) Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted
SE9602263D0 (sv) New amino acid derivatives
DE69626671D1 (de) Fusionsproteine bestehend aus gewebefaktor-kunitzdomäne als inhibitoren des faktors viia
IS5966A (is) Nýjar amídínóafleiður og notkun þeirra sem þrombínhemlar
NO983294L (no) Bowman-Birk inhibitor for hankj°nn dysfunksjon
ES2167364T3 (es) Inhibidores de trombina.
DK1021519T3 (da) Fremgangsmåde til rengøring af kirurgiske instrumenter
GB9216558D0 (en) Modified proteases
DE60134885D1 (de) Antiangiogene polypeptide
EP0326013A3 (en) Novel proteins derived from human alpha2-plasmin inhibitor or proteins similar thereto
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase
UA9703A (uk) Антипротеіназний засіб
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption
GEP19991605B (en) Inhibitor, Its Obtaining and Use
ES2080657A1 (es) Proteasas modificadas.
UA32651C2 (uk) Спосіб напіввідкритої лапаростомії